Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system

Although the global cost of metastatic lung cancer management has increased, the MMC per patient has not notably surged between 2013 and 2021. Drug acquisition MMC increase was offset by reduced full hospitalization MMC (excluding 2020), resulting in no significant uptrend. These results suggest that the global management cost increase is mainly driven by epidemiological and demographic factors. This highlights the importance of continued investment in prevention and in therapeutic innovations that may improve outcomes.